Oct. 31, 2016
Amgen has announced that it will present detailed results from the Phase 3 coronary intravascular imaging trial, the GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound) study, at the upcoming American Heart Association (AHA) Scientific Sessions 2016. This is going to be held in Nov. 12-16 in New Orleans.
The GLAGOV study evaluated whether Repatha® (evolocumab), a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for treating certain patients with high low-density lipoprotein cholesterol (LDL-C), would modify atherosclerotic plaque build-up in the coronary arteries of patients already treated with optimized statin therapy. In September, Amgen announced that the study met its primary and secondary endpoints. As a late-breaking oral presentation, the detailed results from this study will be featured on Tuesday, Nov. 15.
Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, said: “Amgen is committed to unlocking the full potential of biotechnology in the global fight against cardiovascular disease. The robust clinical, observational and health economics data to be presented at AHA 2016 continue to grow our body of knowledge and demonstrate our dedication to improving care for patients with cardiovascular disease.”Amgen Selects Repatha® (Evolocumab) GLAGOV Imaging Study Amongst Data to be Presented at AHA Scientific Sessions 2016last edit: 2016-11-03T17:26:15+00:00da